Chief Financial Officer · Candel Therapeutics, Inc. (CADL)

John Canepa

A named executive officer of Candel Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$449,123

Salary $370,000Stock awards $0

FY2020: $1,319,316

3rd of 3 named executive officers at Candel Therapeutics by FY2021 total.

3 named officers on file for Candel Therapeutics, FY2021

John Canepa’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Candel Therapeutics’s whole pay program stands against its peers

  • Candel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CADL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed September 2, 2022 (DEF 14A).

Free

Get John Canepa’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Canepa compensation by year

Candel Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Candel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$14,231$370,000
Bonus$75,000$0
Stock awards$0$0
Option awards$1,230,085$0
Non-equity incentive$0$74,000
Pension and deferred compensation$0$0
All other$0$5,123
Total$1,319,316$449,123

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed September 2, 2022, accession 0001193125-22-237187, and prior-year filings.

How this page was built: the Candel Therapeutics, Inc. filed document, accession 0001193125-22-237187. Every figure is read from that document and cited to the page and table it appears in. Filed September 2, 2022.

$1.3M
$449K
FY20
FY21
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option48,432—$1.55
Option161,330—$1.55

Per the Outstanding Equity Awards at Fiscal Year-End table in Candel Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Candel Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Paul TakPresident and Chief Executive Officer$956,800
Estuardo Aguilar-CordovaFounder and Former Chief Executive Officer and Chief Scientific Officer (5)$526,386
John Canepa · this pageChief Financial Officer$449,123

The full Candel Therapeutics compensation record

free company brief

This page is one person within Candel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Candel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Canepa's compensation dossier · One-time report. No refunds.